Biotie updates outlook on tozadenant and SYN120 BIOTIE

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jul 30, 2014 at 2:00 AM

Biotie updates outlook on tozadenant and SYN120

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 30 July 2014 at 8.50 a.m. Biotie updates outlook on tozadenant and SYN120 * Tozadenant to advance into Phase 3 in Parkinson's disease within Biotie's proprietary portfolio * SYN120 to advance into Phase 2 in Parkinson's disease dementia, further strengthening Biotie's presence in Parkinson's disease space Biotie has decided to advance tozadenant, its adenosine A2a receptor antagonist for Parkinson's disease, into Phase 3 development as part of the Company's proprietary portfolio. Preparations for Phase 3 development are ongoing, and it is expected that the Phase 3 clinical studies can commence recruitment in H1 2015, as originally planned. Following the decision by UCB Pharma S.A. to return global rights to tozadenant in March 2014, Biotie has been evaluating the most suitable development strategy for this Phase 3 ready asset to maximize its value to shareholders and has concluded that this can be best achieved by continuing with the Phase 3 study within its current portfolio. The Company considers tozadenant to potentially be its most valuable asset given the high unmet medical need in Parkinson's disease and stage of development and is currently evaluating various options, which may include a capital increase, to support the clinical studies and a strong regulatory filing package for tozadenant. As announced in July 2014, Biotie has received a USD 2.0 million (EUR 1.5 million) grant from The Michael J. Fox Foundation (MJFF) for a Phase 2 study in Parkinson's disease dementia. The study is currently expected to begin recruitment around the end of 2014. As a result of this grant and the decision on tozadenant, the previously planned Phase 2 study in Alzheimer's disease will not begin recruitment by the end of 2014 and will be assessed based on the development status of the other products within Biotie's portfolio. Biotie's interim report for January 1 - June 30, 2014 will be published on Wednesday July 30, 2014. Turku, 30 July 2014 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main Media www.biotie.com About tozadenant Tozadenant is an oral, potent and selective adenosine A2a receptor antagonist being developed for the treatment of Parkinson's disease. Tozadenant has displayed clinically relevant and statistically highly significant effects in Parkinson's disease, across multiple pre-specified evaluation metrics, in a 420 patient Phase 2b study completed in December 2012, and it is currently transitioning into Phase 3 development. Biotie holds global rights to tozadenant. Preparations for the tozadenant Phase 3 program in Parkinson's disease are progressing well, and patient recruitment is expected to begin in H1 2015. About SYN120 SYN120 is an oral, potent, dual antagonist of the 5-HT6 and 5-HT2a receptors. These two distinct properties could result in a unique therapeutic profile for SYN120 combining pro-cognitive and antipsychotic activities. SYN120 has completed single and multiple ascending dose Phase 1 clinical studies and a Phase 1 positron emission tomography imaging study to determine therapeutic dose for subsequent Phase 2 studies. SYN120 is currently advancing into Phase 2 development, and the first study will be assessing its safety and efficacy in Parkinson's disease dementia. Biotie holds global rights to SYN120. The Phase 2 study in Parkinson's disease dementia is funded by the Michael J. Fox Foundation. Preparations for the study are underway, and patient recruitment is expected to begin around the end of 2014. About Biotie Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is transitioning into Phase 3 development, and three additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, cocaine dependence, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. [HUG#1842875]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dar Global Eyes Dubai for Strategic Real Estate Moves

Tapping into Dubai's Real Estate Allure Every seasoned investor knows the real estate game ain't for the faint of heart, especially when you’re playing in a market as competitive as Dubai's. But here comes Dar Global Capital Partners (DGCP), throwing their hat into the ring with a fresh strategy centered around high-value real estate. Sure, they aren't new to the...

Medline's Decade-Long WRAP Partnership: More Than Labels

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Federal Law Shifts Landscape for Manufactured Housing

Federal Act Aims to Boost Manufactured Homes Price tags on homes need a reality check, and for a long time, manufactured housing has been in the corner looking for a chance to throw its hat in the ring. Enter the 21st Century ROAD to Housing Act, aiming to finally unlock the potential sitting in our backyards when it comes to these factory-built options. We're talking...

Elbit Systems Lands $200M APAC ISTAR Contracts

Elbit Systems Secures Major Asia-Pacific Deal You know, it's not every day that a defense contractor like Elbit Systems (NASDAQ:ESLT) bags a $200 million deal in the Asia-Pacific region. A big move in a high-stakes game where technology, strategy, and geography collide. This isn't some random supply deal; this involves the cutting edge of defense tech—ISTAR and training...

HCLTech Partners with Rapidus on Semiconductor Future

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...

Miranda Lambert Lights Up Red Kettle Campaign

By Logan Wright Updated Oct 25, 2026 Category News Views 346

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Unlock Technologies Secures $433.1M in HEA Securitization

An Unconventional Wave of Funding Ain't it a sight to see? One year you're hawking tech stocks, the next, you're up to your elbows in home equity agreements (HEAs). That's where Unlock Technologies finds itself. They've just wrapped up their ninth HEA securitization, a hefty $433.1 million, under the watchful eye of D2 Asset Management. This is no minor league...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Reimagining Water: A Crisis and a Call to Action

Time for a Change The head of the World Water Council, Loïc Fauchon, didn't mince words at the 9th Cairo Water Week. He proclaimed the old methods of water management are sinking under a flood of modern challenges. Toss in climate upheavals, ballooning cities, and unpredictable diets, and you've got yourself a swirling mess that traditional strategies just can’t mop...